Prostate Cancer
Conditions
Interventions
None listed
Sponsors
Vaccitech PLC
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Countries
Spain
Outcome results
None listed
A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men with Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer
For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms
Source: EU CTIS · Data processed: Feb 4, 2026